$1.41
+0.06 (+4.44%)
Open$1.34
Previous Close$1.35
Day High$1.45
Day Low$1.34
52W High$5.55
52W Low$1.30
Volume—
Avg Volume137.5K
Market Cap8.09M
P/E Ratio—
EPS$-4.42
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,654.6% upside
Current
$1.41
$1.41
Target
$24.74
$24.74
$16.96
$24.74 avg
$28.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.58M | 4.80M | 3.77M |
| Net Income | 640.0K | 637.0K | 538.3K |
| Profit Margin | 14.0% | 13.3% | 14.3% |
| EBITDA | 1.20M | 1.08M | 968.7K |
| Free Cash Flow | 434.6K | 468.2K | 383.2K |
| Rev Growth | +11.7% | 0.0% | +15.1% |
| Debt/Equity | 0.17 | 0.18 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |